Clinical Trial Update: Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating the safety and immunogenicity of the Ad26.Mos4.HIV and CH505 TF chTrimer vaccine combination in healthy adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ad26.Mos4.HIV (Adenovirus serotype 26 HIV vaccine (Mosaic))
• CH505 TF chTrimer

Snippet

Sponsor: U.S. Army Medical Research and Development Command | Conditions: Human Immunodeficiency Virus | Phase 1 | Status: RECRUITING